-
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
First-trimester combined screening for trisomy 21 at 8-13 weeks.
Wright D, Spencer K, Kagan K, Tørring N, Petersen O, Christou A, Kallikas J, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:404-11. -
Early vaginal bleeding has no impact on markers used in first trimester aneuploidy screening.
Spencer K, Spencer CE, Stamatopoulou A, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:547-50. -
First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers.
Spencer K, Staboulidou I, Nicolaides KH.
Prenat Diagn 2010;30:235-40. -
Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks.
Poon LC, Akolekar R, Lachmann R, Beta J, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;35:662-70. -
Hypertensive disorders in pregnancy: combined screening by uterine artery Doppler, blood pressure and serum PAPP-A at 11-13 weeks.
Poon LC, Stratieva V, Piras S, Piri S, Nicolaides KH.
Prenat Diagn 2010;30:216-23. -
Chorionic villus sampling at 11 to 13 weeks of gestation and hypertensive disorders in pregnancy.
Khalil A, Akolekar R, Pandya P, Syngelaki A, Nicolaides K.
Obstet Gynecol 2010;116:374-80. -
Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan K, Staboulidou I, Cruz JJ, Wright D, Nicolaides K.
Ultrasound Obstet Gynecol 2010;36:542-7. -
Effect of temperature on the measurement of free beta-hCG and PAPP-A concentration.
Cruz JJ, Cruz G, Minekawa R, Maiz N, Nicolaides KH.
Ultrasound Obstet Gynecol 2010;36:141-6. -
First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
Spencer K, Cowans NJ, Avgidou K, Molina F, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;31:15-9. -
First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH.
Obstet Gynecol 2008;31:147-52. -
Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia.
Spencer K, Cowans NJ, Nicolaides KH.
Prenat Diagn 2008;28:7-10. -
Screening for trisomy 21 in twin pregnancies in the first trimester: an update of the impact of chorionicity on maternal serum markers.
Spencer K, Kagan KO, Nicolaides KH.
Prenat Diagn 2008;28:49-52. -
Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
Maiz N, Valencia C, Emmanuel EE, Staboulidou I, Nicolaides KH.
Obstet Gynecol 2008;112:598-605. -
Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO, Wright D, Maiz N, Pandeva I, Nicolaides KH.
Ultrasound Obstet Gynecol 2008;32:488-92.